KBC Group NV Sells 14,492 Shares of United Therapeutics Corporation $UTHR

KBC Group NV cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 62.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,878 shares of the biotechnology company’s stock after selling 14,492 shares during the quarter. KBC Group NV’s holdings in United Therapeutics were worth $5,265,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Torren Management LLC acquired a new stake in shares of United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics during the fourth quarter worth $31,000. International Assets Investment Management LLC increased its position in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB raised its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, Director Jan Malcolm sold 325 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the transaction, the director owned 450 shares in the company, valued at approximately $247,765.50. This represents a 41.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total transaction of $4,586,248.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,960,240.32. The trade was a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 513,333 shares of company stock valued at $286,933,042 in the last 90 days. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 0.5%

Shares of NASDAQ:UTHR opened at $529.53 on Friday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a market capitalization of $22.48 billion, a PE ratio of 19.55, a PEG ratio of 1.76 and a beta of 0.58. The business’s 50 day moving average is $548.68 and its 200-day moving average is $531.41.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.63 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.63 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on UTHR. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada raised their price objective on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $648.33.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.